Advanced medical therapy does not render heart transplantation obsolete for ambulatory end-stage heart failure patients: A debate

Journal of Heart and Lung Transplantation

Volumn 20, Issue 7, 2001, Pages 725-728

  Copeland, Jack G ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE;

AMBULATORY MONITORING; ARTICLE; DISEASE CLASSIFICATION; DISEASE SEVERITY; EXERCISE; HEALTH CARE; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; LIFESTYLE; MEDICAL TECHNOLOGY; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 0034942202     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(01)00247-9     Document Type: Review

References (8)

1. Exercise capacity for survivors of cardiac transplantation or sustained medical therapy for stable heart failure
2. 2, a simple yet enduring standard
3. Heart transplantation, current status
4. Cost-effectiveness analysis in clinical practice, the case of heart failure
5. Cost effectiveness of carvedilol for heart failure
6. Cost effectiveness of captopril therapy after myocardial infarction
7. The Registry of the International Society for Heart and Lung Transplantation; sixteenth official report-1999
8. The impending crisis awaiting cardiac transplantation. Modeling a solution based on selection